{"id":56492,"date":"2023-05-03T14:05:27","date_gmt":"2023-05-03T12:05:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/"},"modified":"2023-05-03T14:05:27","modified_gmt":"2023-05-03T12:05:27","slug":"nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/","title":{"rendered":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline"},"content":{"rendered":"
\n

\nProvides NImmune access to NIMML\u2019s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline<\/i><\/p>\n

\nNImmune will commit up to $15 million in R&D funding for the precision medicine collaboration with NIMML for advancing the LANCL drug pipeline<\/i><\/p>\n

BLACKSBURG, Va.–(BUSINESS WIRE)–NImmune Biopharma <\/b>(“NImmune\u201d), a late-clinical-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics, today announced the launch of a research collaboration with the NIMML Institute (\u201cNIMML\u201d), a nonprofit institute dedicated to the discovery of novel immune-mediated precision medicines. The collaboration strengthens NImmune\u2019s precision immunology capabilities by providing access to NIMML\u2019s TITAN-X advanced computational modeling and A.I. platform for biomarker-driven clinical development. NImmune will also gain access to NIMML\u2019s preclinical, translational, and clinical R&D and regulatory infrastructure.<\/p>\n

<\/a><\/p>\n

\nDr. David Moore, a NIMML Institute Board member and professor emeritus at Virginia Tech, stated, \u201cThe Institute welcomes this alliance with NImmune, whose interests and goals closely align with ours. The synergies gained from this collaboration will advance our mission to further understand the underlying immunological mechanisms that fuel a range of autoimmune diseases and help develop safer and more effective therapeutics.\u201d<\/p>\n

\n“Our collaboration with the NIMML Institute is a natural extension of NImmune’s research and development strategy to create safer and more effective immunoregulatory therapeutics that address the unmet clinical needs of patients with autoimmune diseases,\u201d said Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune. \u201cOur team has already identified novel gene expression signatures that predict the response to treatment for Phase 3-ready omilancor in ulcerative colitis and Phase 2-ready NIM-1324 in lupus. Through our strategic partnership with NIMML, we plan to accelerate the clinical testing and validation of therapeutically relevant gene clusters as biomarkers of response to treatment for omilancor and NIM-1324 in blood and tissue biopsies to determine which patients are most likely to benefit from the LANCL medications and, just as importantly, which are not.”<\/p>\n

\nUnder the terms of the agreement, NIMML will utilize its proprietary TITAN-X drug development platform as well as its industry-leading advanced computational modeling, A.I., and bioinformatics capabilities to implement biomarker-driven approaches in NImmune\u2019s upcoming clinical trials involving the company\u2019s clinical LANCL therapeutics. NIMML will receive up to $15 million in research and development funding from NImmune for costs associated with the precision medicine collaboration. NImmune will be solely responsible for the further development and commercialization of any biomarker-driven therapeutics that are being developed using NIMML\u2019s TITAN-X platform. As part of the strategic relationship, the NIMML Institute will be eligible to receive future payments in regulatory and commercial milestones, as well as tiered single-digit royalties on global product sales for NImmune\u2019s therapeutic pipeline.<\/p>\n

\n\u201cThis agreement significantly strengthens NImmune\u2019s precision immunology capabilities,\u201d continued Dr. Bassaganya-Riera. \u201cWe\u2019re proud to enter this strategic partnership with NIMML, which combines the Institute\u2019s advanced computational platform with our expertise in rapidly translating fundamental scientific discoveries in immunology into safer and more effective medicines for patients with autoimmune diseases such as ulcerative colitis, Crohn\u2019s disease, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. We look forward to working with NIMML to accelerate the clinical development of our high-conviction drug candidates by applying precision medicine approaches.\u201d<\/p>\n

\nAbout NImmune Biopharma
\n
<\/b>NImmune is a late-stage precision immunology biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by a discovery platform that utilizes advanced computational modeling, A.I. and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune\u2019s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. The lead product candidate from NImmune\u2019s discovery platform is omilancor, a wholly-owned Phase 3-ready oral, once-daily, gut-restricted, first-in-class therapeutic targeting LANCL2 for Ulcerative Colitis and Crohn\u2019s disease with registration-directed pivotal clinical trials planned for 2H\u201923. Phase 2 proof-of-concept data for omilancor show potential best in class efficacy and safety. For more information, please visit www.NIMMUNEBIO.COM<\/a> or contact media@nimmunebio.com<\/a>.<\/p>\n

\nAbout NIMML
\n
<\/b>The NIMML Institute is a 501 (c) (3) non-profit foundation focused on applying transdisciplinary, team-science approaches to precision medicine. The NIMML Institute team leads numerous large-scale transdisciplinary projects and is dedicated to solving important societal problems through precision medicine by combining the expertise of immunologists, computational biologists, toxicologists, computational modelers, translational and clinical researchers, and molecular biologists. The Institute is headquartered in Blacksburg, VA. For more information, please visit www.nimml.org<\/a> or contact pio@nimml.org<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Alex Jeffrey\/Iain Hughes
\n
Gasthalter & Co.
\n
NImmune@gasthalter.com<\/a>
212.257.4170<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Provides NImmune access to NIMML\u2019s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline NImmune will commit up to $15 million in R&D funding for the precision medicine collaboration with NIMML for advancing the LANCL drug pipeline BLACKSBURG, Va.–(BUSINESS WIRE)–NImmune Biopharma (“NImmune\u201d), a late-clinical-stage precision immunology … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56492","6":"format-standard","7":"category-industry"},"yoast_head":"\nNImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Provides NImmune access to NIMML\u2019s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline NImmune will commit up to $15 million in R&D funding for the precision medicine collaboration with NIMML for advancing the LANCL drug pipeline BLACKSBURG, Va.–(BUSINESS WIRE)–NImmune Biopharma (“NImmune\u201d), a late-clinical-stage precision immunology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-03T12:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline\",\"datePublished\":\"2023-05-03T12:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/\"},\"wordCount\":784,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230503005103\\\/en\\\/1780977\\\/21\\\/NImmune-logo-Enhanced.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/\",\"name\":\"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230503005103\\\/en\\\/1780977\\\/21\\\/NImmune-logo-Enhanced.jpg\",\"datePublished\":\"2023-05-03T12:05:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230503005103\\\/en\\\/1780977\\\/21\\\/NImmune-logo-Enhanced.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230503005103\\\/en\\\/1780977\\\/21\\\/NImmune-logo-Enhanced.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend","og_description":"Provides NImmune access to NIMML\u2019s TITAN-X advanced computational modeling and A.I. platform to accelerate biomarker-driven clinical development of its LANCL immunoregulatory drug pipeline NImmune will commit up to $15 million in R&D funding for the precision medicine collaboration with NIMML for advancing the LANCL drug pipeline BLACKSBURG, Va.–(BUSINESS WIRE)–NImmune Biopharma (“NImmune\u201d), a late-clinical-stage precision immunology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-03T12:05:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline","datePublished":"2023-05-03T12:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/"},"wordCount":784,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/","url":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/","name":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg","datePublished":"2023-05-03T12:05:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230503005103\/en\/1780977\/21\/NImmune-logo-Enhanced.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nimmune-biopharma-announces-precision-medicine-research-collaboration-with-nimml-institute-to-advance-the-clinical-development-of-its-lancl-immunoregulatory-therapeutic-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NImmune Biopharma Announces Precision Medicine Research Collaboration with NIMML Institute to Advance the Clinical Development of its LANCL Immunoregulatory Therapeutic Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56492"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56492\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}